Caspian Journal of Internal Medicine
Babol University of Medical Sciences
چهارشنبه 29 اسفند 1403
[Archive]
دوره 15، شماره 3 - ( 3-1403 )
جلد 15 شماره 3 صفحات 413-392 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Askari M, Mirmosayyeb O, Fattahi F, Ghoshouni H, Moases Ghaffary E, Shaygannejad V et al . Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Caspian J Intern Med 2024; 15 (3) :392-413
URL: http://caspjim.com/article-1-3964-fa.html
URL: http://caspjim.com/article-1-3964-fa.html
Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): a systematic review and meta-analysis. . 1403; 15 (3) :392-413
چکیده: (1263 مشاهده)
Background: One of the complications of multiple sclerosis (MS) is cognitive impairment (CI). The prevalence of CI is reported variously in previous studies. The goal of this systematic review and meta-analysis to estimate pooled prevalence of CI in patients with MS and also the prevalence of CI based on the type of applied test.
Methods: Two independent researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar as well as gray literature (conference abstracts, references of the references) which were published before up January 2022.
Results: We found 4089 articles by literature search, after deleting duplicates 3174 remained. Ninety articles remained for meta-analysis. The pooled prevalence of CI using all types of tests was 41% (95% CI: 38-44%) (I2=91.7%, p<0.001). The pooled prevalence of CI using BRB test was 39% (95%CI: 36-42%) (I2=89%, p<0.001). The pooled prevalence of CI using BICAMS was 44% (95%CI: 37-51%, I2=95.4%, p<0.001). The pooled prevalence of CI using MACFIMS was 44% (95% CI: 36-53%)(I2=89.3%, p<0.001).
Conclusions: The pooled prevalence of cognitive impairment in patients with MS is estimated as 41%, so CI it should be considered by clinicians.
Methods: Two independent researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar as well as gray literature (conference abstracts, references of the references) which were published before up January 2022.
Results: We found 4089 articles by literature search, after deleting duplicates 3174 remained. Ninety articles remained for meta-analysis. The pooled prevalence of CI using all types of tests was 41% (95% CI: 38-44%) (I2=91.7%, p<0.001). The pooled prevalence of CI using BRB test was 39% (95%CI: 36-42%) (I2=89%, p<0.001). The pooled prevalence of CI using BICAMS was 44% (95%CI: 37-51%, I2=95.4%, p<0.001). The pooled prevalence of CI using MACFIMS was 44% (95% CI: 36-53%)(I2=89.3%, p<0.001).
Conclusions: The pooled prevalence of cognitive impairment in patients with MS is estimated as 41%, so CI it should be considered by clinicians.
نوع مطالعه: Review Article |
موضوع مقاله:
Neurology
دریافت: 1402/3/2 | پذیرش: 1403/1/15 | انتشار: 1403/2/12
دریافت: 1402/3/2 | پذیرش: 1403/1/15 | انتشار: 1403/2/12
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
